286 related articles for article (PubMed ID: 24055694)
21. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study.
Delgado JC; Pavlov IY; Shihab FS
Transpl Immunol; 2009 Dec; 22(1-2):1-4. PubMed ID: 19772921
[TBL] [Abstract][Full Text] [Related]
22. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols.
Hire K; Hering B; Bansal-Pakala P
Transpl Immunol; 2010 Aug; 23(4):209-14. PubMed ID: 20600901
[TBL] [Abstract][Full Text] [Related]
23. Soluble CD30 in renal transplant recipients: is it a good biomarker to predict rejection?
Azarpira N; Aghdaie MH; Malekpour Z
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):31-6. PubMed ID: 20061689
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection.
Ayed K; Abdallah TB; Bardi R; Abderrahim E; Kheder A
Transplant Proc; 2006 Sep; 38(7):2300-2. PubMed ID: 16980071
[TBL] [Abstract][Full Text] [Related]
25. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome.
Ypsilantis E; Key T; Bradley JA; Morgan CH; Tsui S; Parameshwar J; Taylor CJ
J Heart Lung Transplant; 2009 Nov; 28(11):1206-10. PubMed ID: 19782609
[TBL] [Abstract][Full Text] [Related]
26. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study.
Langan LL; D'Orsogna L; Park LP; Hughes TL; Irish A; Luxton G; Witt CS; Christiansen FT
Clin Transpl; 2006; ():219-25. PubMed ID: 18365380
[TBL] [Abstract][Full Text] [Related]
27. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels.
Issa N; Cosio FG; Gloor JM; Sethi S; Dean PG; Moore SB; DeGoey S; Stegall MD
Transplantation; 2008 Sep; 86(5):681-5. PubMed ID: 18791449
[TBL] [Abstract][Full Text] [Related]
28. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
Shooshtarizadeh T; Mohammadali A; Ossareh S; Ataipour Y
Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
[TBL] [Abstract][Full Text] [Related]
29. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
30. High pretransplantation soluble CD30 levels: impact in renal transplantation.
Giannoli C; Bonnet MC; Perrat G; Houillon A; Reydet S; Pouteil-Noble C; Villar E; Lefrançois N; Morelon E; Dubois V
Transplant Proc; 2007 Oct; 39(8):2574-5. PubMed ID: 17954178
[TBL] [Abstract][Full Text] [Related]
31. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection.
Kamali K; Abbasi MA; Farokhi B; Abbasi A; Fallah P; Seifee MH; Ghadimi N; Rezaie AR
Exp Clin Transplant; 2009 Dec; 7(4):237-40. PubMed ID: 20353374
[TBL] [Abstract][Full Text] [Related]
32. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement.
Truong DQ; Darwish AA; Gras J; Wieërs G; Cornet A; Robert A; Mourad M; Malaise J; de Ville de Goyet J; Reding R; Latinne D
Transpl Immunol; 2007 Jun; 17(4):283-7. PubMed ID: 17493532
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
34. CD30, a marker to detect the high-risk kidney transplant recipients.
Spiridon C; Nikaein A; Lerman M; Hunt J; Dickerman R; Mack M
Clin Transplant; 2008; 22(6):765-9. PubMed ID: 19040559
[TBL] [Abstract][Full Text] [Related]
35. Functional assessment of immune markers of graft rejection: a comprehensive study in live-related donor renal transplantation.
Panigrahi A; Deka R; Bhowmik D; Dash SC; Tiwari SC; Guleria S; Mehta SN; Mehra NK
Clin Transplant; 2006; 20(1):85-90. PubMed ID: 16556160
[TBL] [Abstract][Full Text] [Related]
36. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
37. High serum soluble CD30 does not predict acute rejection in liver transplant patients.
Matinlauri I; Höckerstedt K; Isoniemi H
Transplant Proc; 2006 Dec; 38(10):3601-4. PubMed ID: 17175343
[TBL] [Abstract][Full Text] [Related]
38. Serial soluble CD30 measurements as a predictor of kidney graft outcome.
Halim MA; Al-Otaibi T; Al-Muzairai I; Mansour M; Tawab KA; Awadain WH; Balaha MA; Said T; Nair P; Nampoory MR
Transplant Proc; 2010 Apr; 42(3):801-3. PubMed ID: 20430176
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of pre transplant T-cell activation status by soluble CD 30 determination.
Abbas K; Muzaffar R; Zafar MN; Mubarak M; Naqvi SA; Rizvi SA
J Pak Med Assoc; 2009 Apr; 59(4):212-5. PubMed ID: 19402280
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
